MicroPort Received Re-registration for GnRH Infusion Pump

Recently, La Fenice® GnRH Infusion Pump, independently developed by MicroPort Lifesciences Co., Ltd. which is a subsidiary of MicroPort group, received re-registration from Shanghai Food and Drug Administration (SFDA). Compared to the previous generation of the product, the new La Fenice® GnRH Infusion Pump added various featues and functionalities such as vibration alarm, pictorial descriptions in the user manual, in which to meet the requirements of laws and regulations.
GnRH Infusion Pump is used for the treatment of Idiopathic HypogonadotropicHypogonadism (IHH) which is also known as Kallmann Syndrome. In recent years, China's infertility prevalence rate has risen to 12.5%, including male's morbidity of Kallmann Syndrome is about 1/2000, the female is about 1/10000. Although our country for the diagnosis of such disorders has been in the leading level in the world, but it has been the lack of appropriate therapy. It is the first pulsatile GnRH infusion pump in China, which fills the market blank of domestic similar products.
Equipped with pulse infusion via micro pumptechnology, GnRH infusion pump stimulates hypophysis to excrete Follicle-Stimulating Hormone (FSH)/ luteinizing hormone (LH) by simulating pulse excretion of human gonadotropin-releasing hormone(GnRH) in order to make patients recover from abnormally physiological regulated function. This treatment can promote and maintain the development of secondary sex characteristics, restore fertility, improve adult growth hormone deficiency, increase bone density, reduce the risk of cardiovascular events.
Presently, MicroPort has been promoting GnRH infusion pump therapy thoughout the China. Besides Shanghai Ruijin Hospital, MicroPort has successfully built the promotional centers in various large state-owned hospitals in Hebei, Henan, Xinjiang, Shaanxi, Guangdong, Guangxi, Beijing, Qingdao and other provinces.